Wright Investors Service Holdings, Inc. - Quarter Report: 2007 June (Form 10-Q)
k
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
10-Q
(Mark
One)
x
|
QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE
ACT OF
1934
|
|
For
the quarterly period ended June 30,
2007
|
|
or
|
o
|
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE
ACT OF
1934
|
|
For
the transition period from _____ to
_____
|
Commission
File
Number:
000-50587
NATIONAL
PATENT DEVELOPMENT CORPORATION
(Exact
Name of Registrant as Specified in its Charter)
Delaware
|
|
13-4005439
|
(State
or other jurisdiction of
incorporation
or organization
|
|
(I.R.S.
Employer
Identification
No.)
|
10
East 40th Street, Suite 3110, New York, NY
|
10016
|
|
(Address
of principal executive offices)
|
(Zip
code)
|
(646)
742-1600
|
(Registrant’s
telephone number, including area
code)
|
Indicate
by check mark whether the registrant: (1) has filed all reports required
to be
filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the
preceding 12 months (or for such shorter period that the registrant was
required
to file such reports), and (2) has been subject to such filing requirements
for
the past 90 days. Yes x No o
Indicate
by check mark whether the registrant is a large accelerated filer, an
accelerated filer, or a non-accelerated filer. See definition of accelerated
filer and large accelerated filer in Rule 12b-2 of the Exchange Act. (Check
one):
Large
accelerated filer o Accelerated
filer o
Non-accelerated
filer x
Indicate
by check mark whether the registrant is a shell company (as defined in
Rule
12b-2 of the Exchange Act). Yes o No x
As
of
August 10, 2007, there were 17,884,969 shares of the registrant’s common stock,
$0.01 par value, outstanding.
NATIONAL
PATENT DEVELOPMENT CORPORATION AND SUBSIDIARIES
TABLE
OF CONTENTS
|
|
|
Page
No.
|
Part
I.
Financial Information
|
|||
Item
1.
|
Financial
Statements
|
|
|
|
Condensed
Consolidated Statements of Operations-
|
|
|
|
Three months and six months ended
|
|
|
|
June 30, 2007 and 2006 (unaudited)
|
1
|
|
|
Condensed
Consolidated Statements of Comprehensive Loss-
|
|
|
|
Three months and six months ended
|
|
|
|
June 30, 2007 and 2006 (unaudited)
|
2
|
|
|
Condensed
Consolidated Balance Sheets -
|
|
|
|
June 30, 2007 (unaudited) and December 31, 2006
|
3
|
|
|
Condensed
Consolidated Statements of Cash Flows -
|
|
|
|
Six months ended June 30, 2007 and 2006 (unaudited)
|
4
|
|
|
Notes
to Condensed Consolidated Financial Statements
|
5
|
|
Item
2.
|
Management's
Discussion and Analysis of Financial
|
|
|
|
Condition and Results of Operations
|
21
|
|
Item
3.
|
Quantitative
and Qualitative Disclosure about Market Risk
|
34
|
|
Item
4.
|
Controls
and Procedures
|
|
34
|
Part
II. Other Information
|
|||
Item
2.
|
Unregistered
Sales of Equity Securities and Use of Proceeds
|
35
|
|
Item
6.
|
Exhibits
|
|
35
|
Signatures
|
|
36
|
PART
I. FINANCIAL INFORMATION
Item
1. Financial Statements
NATIONAL
PATENT DEVELOPMENT CORPORATION AND SUBSIDIARIES
CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in
thousands, except per share data)
Three
months ended
|
Six
months ended
|
|||||||||||||||
June
30,
|
June
30,
|
|||||||||||||||
2007
|
2006
|
2007
|
2006
|
|||||||||||||
Sales
|
$ |
38,134
|
$ |
31,161
|
$ |
70,065
|
$ |
62,366
|
||||||||
Cost
of sales
|
31,344
|
25,627
|
58,185
|
51,619
|
||||||||||||
Gross
margin
|
6,790
|
5,534
|
11,880
|
10,747
|
||||||||||||
Selling,
general and administrative
expenses
|
(6,269 | ) | (5,073 | ) | (10,971 | ) | (9,795 | ) | ||||||||
Operating profit
|
521
|
461
|
909
|
952
|
||||||||||||
Interest
expense
|
(506 | ) | (464 | ) | (832 | ) | (843 | ) | ||||||||
Gain
on exchange of Valera for
Indevus shares |
17,031
|
17,031
|
||||||||||||||
Investment
and other income (loss)
|
(835 | ) |
55
|
(769 | ) | (182 | ) | |||||||||
Income
(loss) before income tax
expense and minority interest |
16,211
|
52
|
16,339
|
(73 | ) | |||||||||||
Income
tax expense
|
(355 | ) | (125 | ) | (715 | ) | (346 | ) | ||||||||
Income
(loss) before minority interest
|
15,856
|
(73 | ) |
15,624
|
(419 | ) | ||||||||||
Minority
interest
|
(241 | ) | (45 | ) | (436 | ) | (136 | ) | ||||||||
Net
income (loss)
|
$ |
15,615
|
$ | (118 | ) | $ |
15,188
|
$ | (555 | ) | ||||||
Net
income (loss) per share
|
||||||||||||||||
Basic
|
$ | 0.87 |
$
|
(0.01 | ) |
$
|
0.85 |
$
|
(0.03 | ) | ||||||
Diluted
|
$ |
0.87
|
$ | (0.01 | ) | $ |
0.85
|
$ | (0.03 | ) |
See
accompanying notes to condensed consolidated financial
statements.
1
NATIONAL
PATENT DEVELOPMENT CORPORATION AND SUBSIDIARIES
CONDENSED
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(unaudited)
(in
thousands)
Three
months ended
|
Six
months ended
|
|||||||||||||||
June
30,
|
June
30,
|
|||||||||||||||
2007
|
2006
|
2007
|
2006
|
|||||||||||||
Net
income (loss)
|
$ |
15,615
|
$ | (118 | ) | $ |
15,188
|
$ | (555 | ) | ||||||
Other
comprehensive income (loss),
before tax: |
||||||||||||||||
Net
unrealized gain (loss) on
available-for-sale-securities (a) |
(796 | ) |
286
|
(618 | ) |
4,582
|
||||||||||
Reclassification
adjustment
principally for gain on exchange of Valera securities recognized in merger included in net income |
(4,614 | ) |
-
|
(4,614 | ) |
-
|
||||||||||
Net
unrealized gain (loss) on
interest rate swap, net
of minority interest
|
2
|
21
|
(46 | ) |
66
|
|||||||||||
Comprehensive
income before tax
|
10,207
|
189
|
9,910
|
4,093
|
||||||||||||
Income
tax (expense) benefit
related to items of other comprehensive income (loss) |
3
|
(8 | ) |
18
|
(26 | ) | ||||||||||
Comprehensive
income
|
$ |
10,210
|
$ |
181
|
$ |
9,928
|
$ |
4,067
|
(a) Includes
gains of $65 for the three months ended June 30, 2007 and $231 for the six
months ended June 30, 2007 of Valera to date of merger and loss of $763 for
the
three and six months ended June 30, 2007 of Indevus from date of
merger.
See
accompanying notes to condensed consolidated financial
statements.
2
NATIONAL
PATENT DEVELOPMENT CORPORATION AND SUBSIDIARIES
CONDENSED
CONSOLIDATED BALANCE SHEETS
(in
thousands)
June
30,
|
December
31,
|
|||||||
2007
|
2006
|
|||||||
Assets
|
(unaudited)
|
|||||||
Current
assets
|
||||||||
Cash
and cash equivalents
|
$ |
4,062
|
$ |
4,485
|
||||
Accounts
receivable, less allowance
|
||||||||
for
doubtful accounts of $497 and $566
|
22,974
|
11,939
|
||||||
Receivable
from GP Strategies Corporation
|
251
|
|||||||
Inventories
|
27,655
|
22,535
|
||||||
Prepaid
expenses and other current assets
|
500
|
724
|
||||||
Investment
in marketable securities of Indevus, available for sale
|
15,799
|
|||||||
Deferred
tax asset
|
597
|
791
|
||||||
Total
current assets
|
71,587
|
40,725
|
||||||
Property,
plant and equipment, net
|
3,406
|
2,925
|
||||||
Investment
in Valera including available for sale securities of
$4,823
|
5,995
|
|||||||
Other
marketable securities available for sale
|
244
|
343
|
||||||
Deferred
tax asset
|
193
|
|||||||
Other
assets
|
3,847
|
3,286
|
||||||
Total
assets
|
$ |
79,277
|
$ |
53,234
|
||||
Liabilities
and stockholder’s equity
|
||||||||
Current
liabilities
|
||||||||
Current
maturities of long-term debt
|
$ |
257
|
$ |
151
|
||||
Short
term borrowings
|
25,012
|
18,414
|
||||||
Accounts
payable and accrued expenses
|
17,883
|
9,978
|
||||||
Payable
to GP Strategies Corporation
|
74
|
|
||||||
Total
current liabilities
|
43,226
|
28,543
|
||||||
Long-term
debt less current maturities
|
1,570
|
1,332
|
||||||
Deferred
tax liability
|
279
|
279
|
||||||
Other
liabilities
|
1
|
247
|
||||||
Minority
interest
Common
stock subject to exchange rights
|
2,770
477
|
1,696
|
||||||
Stockholder’s
equity
|
||||||||
Common
Stock
|
180
|
178
|
||||||
Additional
paid-in capital
|
26,097
|
25,990
|
||||||
Retained
earnings (deficit)
|
6,011
|
(9,177 | ) | |||||
Accumulated
other comprehensive (loss) income
|
(926 | ) |
4,334
|
|||||
Treasury
stock
|
(408 | ) | (188 | ) | ||||
Total
stockholder’s equity
|
30,954
|
21,137
|
||||||
Total
liabilities and stockholder’s equity
|
$ |
79,277
|
$ |
53,234
|
See
accompanying notes to condensed consolidated financial
statements.
3
NATIONAL
PATENT DEVELOPMENT CORPORATION AND SUBSIDIARIES
CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(in
thousands)
Six
months ended
|
||||||||
June
30,
|
||||||||
2007
|
2006
|
|||||||
Cash
flows from operations:
|
||||||||
Net
income (loss)
|
$ |
15,188
|
$ | (555 | ) | |||
Adjustments
to reconcile net income (loss) to
|
||||||||
net
cash used in operating activities:
|
||||||||
Depreciation
and amortization
|
368
|
388
|
||||||
Minority
interest
|
436
|
136
|
||||||
Expenses
paid in common stock
|
31
|
44
|
||||||
Deferred
income taxes
|
-
|
(7 | ) | |||||
Stock
based compensation
|
248 | |||||||
Gain
on issuance of stock by subsidiary
|
(1 | ) | ||||||
Gain
on exchange of Valera for Indevus shares
|
(17,031 | ) | ||||||
Loss
on sales of Indevus shares
|
236
|
|||||||
Changes
in other operating items, net of effect of acquisition of
Right-Way
|
(3,071 | ) | (3,152 | ) | ||||
Net
cash used in operations
|
(3,596 | ) | (3,146 | ) | ||||
Cash
flows from investing activities:
|
||||||||
Additions
to property, plant and equipment, net
|
(849 | ) | (297 | ) | ||||
Acquisition
of additional interest in Five Star
|
(106 | ) | ||||||
Acquisition
of Right-Way by Five Star
|
(3,399 | ) | ||||||
Repayment
of receivable from GP Strategies
|
325
|
417
|
||||||
Net
cash (used in) provided by investing
activities
|
(4,029 | ) |
120
|
|||||
Cash
flows from financing activities:
|
||||||||
Proceeds
from sale of common stock
|
480
|
|||||||
Purchase
of treasury stock
|
(220 | ) | ||||||
Proceeds
from short-term borrowings
|
6,598
|
2,773
|
||||||
Proceeds
from (repayment of) long-term debt, net
|
344
|
(179 | ) | |||||
Net
cash provided by financing activities
|
7,202
|
2,594
|
||||||
Net
decrease in cash and cash equivalents
|
(423 | ) | (432 | ) | ||||
Cash
and cash equivalents at beginning of period
|
4,485
|
5,115
|
||||||
Cash
and cash equivalents at end of period
|
$ |
4,062
|
$ |
4,683
|
||||
Cash
paid for:
|
||||||||
Interest
|
$ |
897
|
$ |
937
|
||||
Taxes
|
$ |
18
|
$ |
80
|
||||
Non
cash investing activities:
|
||||||||
Acquisition
of stock of Indevus in exchange for stock of
Valera in a merger transaction |
$ |
14,960
|
See
accompanying notes to the condensed consolidated financial
statements.
4
NATIONAL
PATENT DEVELOPMENT CORPORATION AND
SUBSIDIARIES
Notes
to
Condensed Consolidated Financial Statements
Three and six months ended June 30, 2007 and 2006
(unaudited)
Three and six months ended June 30, 2007 and 2006
(unaudited)
1. Basis
of presentation and summary of significant accounting
policies
Basis
of presentation
The
accompanying Condensed Consolidated Statements of Operations for the three
months and six months ended June 30, 2007 and 2006, the Condensed Consolidated
Statements of Comprehensive Loss for the three months and six months ended
June
30, 2007 and 2006, the Condensed Consolidated Balance Sheet as of June 30,
2007
and the Condensed Consolidated Statements of Cash Flows for the six months
ended
June 30, 2007 and 2006 have not been audited, but have been prepared in
conformity with accounting principles generally accepted in the United States
for interim financial information and with the instructions to Form 10-Q and
Article 10 of Regulation S-X. These financial statements should be
read in conjunction with the audited consolidated financial statements and
notes
thereto for the year ended December 31, 2006 as presented in our Annual Report
on Form 10-K. In the opinion of management, this interim information
includes all material adjustments, which are of a normal and recurring nature,
necessary for a fair presentation. The results for the 2007 interim
periods are not necessarily indicative of results to be expected for the entire
year.
The
Company’s 58% owned subsidiary, Five Star Products, Inc. (“Five Star”), is
engaged in the wholesale distribution of home decorating, hardware and finishing
products. It serves over 3,000 independent retail dealers in the
Northeast and Mid-Atlantic States. Products distributed include paint
sundry items, interior and exterior stains, brushes, rollers, caulking compounds
and hardware products. In January 2007, the Company purchased 305,137
shares of Five Star common stock, which represented 2% of the then outstanding
Five Star common stock, for $106,000.
On
April
5, 2007, Five Star acquired substantially all the assets of Right-Way Dealer
Warehouse, Inc. ("Right-Way") including all of Right-Way's Brooklyn Cash &
Carry business and operations, which sells paint sundries and hardware supplies
to local retail stores (see Note 13).
Revenue
recognition. Revenue on product sales is recognized at the point
in time when the product has been shipped, title and risk of loss has been
transferred to the customer, and the following conditions are met: persuasive
evidence of an arrangement exists, the price is fixed and determinable, and
collectibility of the resulting receivable is reasonably
assured. Allowances for estimated returns and allowances are
recognized when sales are recorded.
Shipping
and handling costs. Shipping and handling costs are included as
a part of selling, general and administrative expense. These
cost amounted to $1,444,000, $2,743,000, $1,301,000 and $2,545,000, for the
three months and six months ended June 30, 2007 and 2006,
respectively.
(Continued)
5
NATIONAL
PATENT DEVELOPMENT CORPORATION AND
SUBSIDIARIES
Notes
to
Condensed Consolidated Financial Statements
Three and six months ended June 30, 2007 and 2006
(unaudited)
Three and six months ended June 30, 2007 and 2006
(unaudited)
Inventories. Inventories
are valued at the lower of cost or market, using the first-in, first-out
method.
Derivatives
and hedging activities. The interest rate swap and interest rate
collar entered into by Five Star in connection with its Loan and Security
Agreement (see Note 7) is being accounted for under SFAS No. 133, as amended,
"Accounting for Derivative Instruments and Hedging Activities." SFAS No. 133
requires all derivatives to be recognized in the balance sheet at fair value.
Derivatives that are not hedges must be adjusted to fair value through earnings.
If the derivative is a cash flow hedge, changes in the fair value of the
derivative are recognized in other comprehensive income until the hedged item
is
recognized in earnings. The ineffective portion of a derivative's change in
fair
value is immediately recognized in earnings. Changes in the fair value of the
interest rate swap, which has been designated as a cash flow hedge, were
recognized in other comprehensive income. Changes in the fair value
of the interest rate collar are recognized in earnings. For the three
and six months ended June 30, 2007 the Company recognized a gain of $6,000
and
$5,000, respectively, and for the three and six months ended June 30, 2006
the
Company recognized a loss of $11,000 and $16,000, respectively, as part of
other
income, for the changes in the fair value of the interest rate
collar.
2.
|
Accounting
for uncertainty in income taxes - FASB Interpretation
No. 48
|
In
June 2006, the Financial Accounting
Standards Board issued FASB Interpretation No. 48, “Accounting for Uncertainty
in Income Taxes – an interpretation of FASB Statement No. 109” (“FIN 48”), which
prescribes a recognition threshold and measurement attribute for the financial
statement recognition and measurement of a tax position taken or expected to
be
taken in a tax return. FIN 48 also provides guidance on
de-recognition, classification, interest and penalties, accounting in interim
periods, disclosure and transition. FIN 48 is effective for fiscal
years beginning after December 15, 2006. The
adoption of FIN 48 in
the first quarter of 2007 did not have any
effect on the Company’s consolidated financial
statements. The
Company files income tax returns in
the U.S. federal jurisdiction and various state jurisdictions. The statute
of
limitations for assessment of federal, state & local income taxes by the
taxing authorities is open for years 2004 to 2006.
3. Treasury
Stock
On
December 15, 2006, the Company’s Board of Directors authorized the Company to
repurchase up to 2,000,000 shares, or approximately 11%, of its outstanding
shares of common stock from time to time either in open market or privately
negotiated transactions. At June 30, 2007, the Company had
repurchased 192,450 shares of its common stock for $408,000.
(Continued)
6
NATIONAL
PATENT DEVELOPMENT CORPORATION AND
SUBSIDIARIES
Notes
to
Condensed Consolidated Financial Statements
Three and six months ended June 30, 2007 and 2006
(unaudited)
Three and six months ended June 30, 2007 and 2006
(unaudited)
4. Incentive
stock plans and stock based compensation
The
Company and Five Star have stock-based compensation plans for employees and
non-employee members of their respective Boards of Directors. The plans provide
for discretionary grants of stock options, restricted stock shares, and other
stock-based awards. The Company’s plan is administered by the Compensation
Committee of the Board of Directors, consisting of non-employee directors,
and
the Five Star plan is administered by Five Star’s entire Board of
Directors.
Company
Stock Option Plan
On
November 3, 2003, GP Strategies Corporation (“GPS”), which at the time was the
Company’s parent, adopted an Incentive Stock Plan (the “2003 Plan”) under which
1,750,000 shares of the Company’s common stock are available for grant to
employees, directors and outside service providers. The plan permits
awards of incentive stock options, nonqualified stock options, restricted stock,
stock units, performance shares, performance units and other incentives payable
in cash or in shares of the Company’s common stock. The term of any
option granted under the 2003 Plan will not exceed ten years from the date
of
grant and, in the case of incentive stock options granted to a 10% or greater
holder in the total voting stock of the Company, three years from the date
of
grant. The exercise price of any option will not be less than the
fair market value of the Common Stock on the date of grant or, in the case
of
incentive stock options granted to a 10% or greater holder in the total voting
stock, 110% of such fair market value.
On
March
1, 2007 the Company’s
Board of Directors approved and adopted an amendment, subject to stockholder
approval, (the “Amendment”) to the 2003 Plan increasing the aggregate number of
shares of Company common stock issuable under the 2003 Plan from 1,750,000
shares to 3,500,000 shares (subject to adjustment as provided in the 2003 Plan),
and increasing the per person limitation in the 2003 Plan from 250,000 shares
to
2,500,000 shares. The Company expects to submit the Amendment to the
Company's stockholders for approval at the Company's 2007 Annual Stockholders
Meeting.
In
March
2007, the Company granted an aggregate of 3,200,000 nonqualified stock options
under the 2003 Plan (including the options referred to in Note 12(a) and (b)),
of which 632,830 were granted under the terms of the 2003 Plan as presently
approved by the Company’s shareholders and the remainder were granted subject to
shareholder approval of the amendments referred to below. The Company
determined the estimated aggregate fair value of the 632,830 options which
are
not subject to shareholder approval on the date of grant to be $673,000 based
on
the Black-Scholes valuation model using the following assumptions: expected
volatility of 49.27%, dividend yield of 0%, risk free interest of 4.5% and
an
expected life of 4 years. Upon shareholder approval (see below), the
Company will determine the estimated aggregate fair value of the remaining
2,567,170 options based upon the closing price of the Company’s common stock on
that date using the Black-Scholes valuation model.
(Continued)
7
NATIONAL
PATENT DEVELOPMENT CORPORATION AND
SUBSIDIARIES
Notes
to
Condensed Consolidated Financial Statements
Three and six months ended June 30, 2007 and 2006
(unaudited)
Three and six months ended June 30, 2007 and 2006
(unaudited)
A
summary
of the Company’s stock option activity as of June 30, 2007, and changes during
the six months then ended, which includes option activity described
above, is presented below:
Stock
Options
|
Weighted
Average
Exercise
Price |
Weighted
Average
Contractual
Term
|
Aggregate
Intrinsic
Value |
|||||||||||||
Outstanding
at January 1, 2007
|
|
|||||||||||||||
Granted
|
632,830
|
$ |
2.45
|
|||||||||||||
Exercised
|
||||||||||||||||
Forfeited
or expired
|
||||||||||||||||
Outstanding
at June 30, 2007
|
632,830
|
2.45
|
3.3
|
$ | 221,000 | * | ||||||||||
Vested
at June 30, 2007
|
|
|||||||||||||||
Exercisable
at June 30, 2007
|
|
___________________
*The
intrinsic value of a stock option is the amount by which the market value of
the
underlying stock exceeds the exercise price of the option.
Five
Star Stock Option Plan
On
January 1, 1994, Five Star's Board of Directors adopted the Five Star Products,
Inc. 1994 Stock Option Plan (the "1994 Five Star Plan"), which became
effective when approved by the Five Star shareholders on August 5,
1994. On January 1, 2002, the Board of Directors amended the 1994
Five Star Plan increasing the total number of shares of common stock to
4,000,000 shares reserved for issuance, subject to
adjustment. Options could be granted to any director, officer or
other key employee of Five Star and its subsidiaries, and to consultants and
other individuals providing services to Five Star. Although there are
outstanding options which have been granted under 1994 Five Star Plan no further
options may be granted under this Plan.
On
March
1, 2007, the Board of Directors of Five Star adopted the Five Star Products,
Inc. 2007 Incentive Stock Plan (the “2007 Five Star Plan”), subject to the
approval of the shareholders of Five Star. Five Star expects to
submit the 2007 Five Star Plan to its shareholders for approval at the Five
Star
2007 Annual Stockholders Meeting. Based upon the Company’s intent to
vote its shares of Five Star in favor of the 2007 Five Star Plan, which will
assure its approval, the financial effect of all options and restricted stock
issued under the 2007 Five Star Plan are reflected as if shareholder approval
had been obtained prior to the date of grant. Under the 2007 Five Star Plan,
Five Star may grant awards of non-qualified stock options, incentive stock
options (if the 2007 Five Star Plan is submitted to and approved by stockholders
of Five Star prior to February 28, 2008), restricted stock, stock units,
performance shares, performance units, and other incentives payable in cash
or
in shares of Five Star’s common stock to officers, employees or members of the
Board of Directors of Five Star and its subsidiaries. Five Star is authorized
to grant an aggregate of 2,500,000 shares of Five Star Common Stock under the
2007 Five Star Plan. Five Star may issue new shares or use shares
held in treasury to deliver shares for equity grants or upon exercise of
non-qualified stock options.
(Continued)
8
NATIONAL
PATENT DEVELOPMENT CORPORATION AND
SUBSIDIARIES
Notes
to
Condensed Consolidated Financial Statements
Three and six months ended June 30, 2007 and 2006
(unaudited)
Three and six months ended June 30, 2007 and 2006
(unaudited)
On
March
2, 2007, subject to shareholder approval of the 2007 Five Star Plan, Five Star
granted options under the 2007 Five Star Plan to purchase 250,000 shares of
Five
Star’s common stock to two employees and increased the exercise price and EBITDA
target of 400,000 options granted to an employee on October 18, 2006. The
exercise price of the 650,000 options was equal to $0.38, the average of the
closing bid and asked prices of the common stock on March 2, 2007. The options
will vest if Five Star meets certain EBITDA targets over the next three years
provided that the option holders continue to be employees of Five Star. Five
Star determined the estimated aggregate fair value of these options on the
date
of grant to be $185,000 based on the Black-Scholes valuation
model. Achievement of performance criteria was determined in
probable in March 2007 and therefore compensation expense of $15,400 and
$20,600 was recognized during the quarter and six months ended June 30,
2007.
On
April
5, 2007, in connection with an employment agreement entered into
with the principal of Right-Way Dealer Warehouse, Inc. (see Note 13),
Five Star granted him an option to purchase 200,000 shares of Five Star common
stock under the 2007 Five Star Plan, subject to shareholder approval. The
options will vest if Five Star meets certain EBITDA targets over the next three
years proved that the option holder continues to be employed by Five Star Group.
At June 30, 2007, Five Star determined that it was probable it would meet 2007
EBITDA targets and accordingly recorded a charge of $8,000 for the three and
six
months ended June 30, 2007.
(Continued)
9
NATIONAL
PATENT DEVELOPMENT CORPORATION AND
SUBSIDIARIES
Notes
to
Condensed Consolidated Financial Statements
Three and six months ended June 30, 2007 and 2006
(unaudited)
Three and six months ended June 30, 2007 and 2006
(unaudited)
A
summary
of Five Star’s stock option activity as of June 30, 2007, and changes during the
six months then ended, which includes option activity described
above, is presented below:
Stock
Options
|
Weighted
Average
Exercise
Price |
Weighted
Average
Contractual
Term
|
Aggregate
Intrinsic
Value |
|||||||||||||
Outstanding
at January 1, 2007
|
1,050,000
|
$ |
0.16
|
|||||||||||||
Granted
|
450,000
|
.47
|
||||||||||||||
Exercised
|
(50,000 | ) |
.15
|
$ | 17,500 | * | ||||||||||
Forfeited
or Expired
|
(450,000 | ) |
.16
|
|||||||||||||
Outstanding
at June 30, 2007
|
1,000,000
|
.42
|
3.3
|
219,000 | * | |||||||||||
Vested
at June 30, 2007
|
150,000
|
.16
|
.3
|
|||||||||||||
Exercisable
at June 30, 2007
|
150,000
|
.16
|
.3
|
72,500 | * |
___________________
*The
intrinsic value of a stock option is the amount by which the market value of
the
underlying stock exceeds the exercise price of the option.
During
the six month period ended June 30, 2007, 400,000 options outstanding as of
January 1, 2006 were modified.
On
March
2, 2007, subject to Five Star shareholder approval, Five Star granted 1,000,000
shares of restricted stock to its chief executive officer (see Note 12(b))
valued at $.38 per share under the 2007 Five Star Plan. This restricted stock
will vest if Five Star meets certain EBITDA targets over the next three years
provided that he continues to be employed by Five Star or the Company. In March
2007, Five Star determined that achievement of the performance criteria was
probable and therefore compensation expense of $31,000 and $42,000 was
recognized during the quarter and six months ended June 30, 2007.
(Continued)
10
NATIONAL
PATENT DEVELOPMENT CORPORATION AND
SUBSIDIARIES
Notes
to
Condensed Consolidated Financial Statements
Three and six months ended June 30, 2007 and 2006
(unaudited)
Three and six months ended June 30, 2007 and 2006
(unaudited)
5. Per
share data
Income
(loss) per share for the three months and six months ended June 30, 2007 and
2006 are calculated as follows (in thousands, except per share
amounts):
Three
months ended
|
Six
months ended
|
|||||||||||||||
June
30,
|
June
30,
|
|||||||||||||||
2007
|
2006
|
2007
|
2006
|
|||||||||||||
Basic
EPS
|
||||||||||||||||
Net
income (loss)
|
$ |
15,615
|
$ | (118 | ) | $ |
15,188
|
$ | (555 | ) | ||||||
Weighted
average shares
|
||||||||||||||||
outstanding
|
17,877
|
17,834
|
17,812
|
17,831
|
||||||||||||
Basic
earnings (loss) per share
|
$ |
.87
|
$ | (.01 | ) | $ |
.85
|
$ | (.03 | ) | ||||||
Diluted EPS | ||||||||||||||||
Net
income (loss)
|
$ |
15,615
|
$ | (118 | ) | $ | 15,188 | $ | (555 | ) | ||||||
Weighted
average
shares
outstanding
|
17,877 | 17,834 | 17,811 | 17,831 | ||||||||||||
Dilutive
effect of stock options
|
67 | 24 | ||||||||||||||
Diluted
weighted average shares outstanding
|
17,944
|
17,834
|
17,835
|
17,831
|
||||||||||||
Diluted
earnings (loss)
per
share
|
$ |
.87
|
$ | (.01 | ) | $ | .85 | $ | (.03 | ) |
Outstanding
warrants to acquire 1,423,887 common shares issued in December 2004 were not
included in the diluted computation, as their effect would be
anti-dilutive. In addition, the effect on the diluted computation of
outstanding options and the convertible note of Five Star (see Note 12(d))
was
anti-dilutive and accordingly did not effect such computation.
(Continued)
11
NATIONAL
PATENT DEVELOPMENT CORPORATION AND
SUBSIDIARIES
Notes
to
Condensed Consolidated Financial Statements
Three and six months ended June 30, 2007 and 2006
(unaudited)
Three and six months ended June 30, 2007 and 2006
(unaudited)
6. Long-term
debt
Long-term
debt
Long-term
debt is comprised of the following (in thousands):
June
30,
|
December
31,
|
|||||||
2007
|
2006
|
|||||||
MXL
Pennsylvania Mortgage (a)
|
$ |
1,055
|
$ |
1,105
|
||||
MXL
term loan (b)
|
772
|
377
|
||||||
Capital
lease obligations
|
-
|
1
|
||||||
1,827
|
1,483
|
|||||||
Less
current maturities
|
(257 | ) | (151 | ) | ||||
$ |
1,570
|
$ |
1,332
|
|
a)
|
The
loan, which is collateralized by real estate and fixtures, requires
monthly repayments of $8,333 plus interest at 2.5% above the one
month
LIBOR rate and matures on March 8, 2011, when the remaining amount
outstanding of approximately $680,000 is due in full. The loan
is guaranteed by GP Strategies Corporation (“GPS”), formerly the parent
entity of MXL and the Company, under an agreement entered into
concurrently with GPS’s spin-off of these
entities.
|
|
b)
|
On
November 27, 2006, MXL entered into a 5 year $785,000 Term Loan
for the financing of machinery and equipment at 2.5% above the one
month
LIBOR rate, or .25% above the bank’s prime lending rate, as
applicable. From November 2006 through May 2007 the Bank may
disburse funds to MXL, and MXL will pay on a monthly basis, all accrued
interest due the bank. In May 2007 the balance borrowed
converted to a five year Term Loan, with monthly payments of principal
and
accrued interest through May 2012. The Term Loan is guaranteed by
the
Company and collateralized by MXL’s Lancaster, PA
property.
|
7. Short-term
borrowings
Five
Star short-term borrowings
In
2003,
Five Star obtained a Loan and Security Agreement (the “Loan Agreement”) with
Bank of America Business Capital (formerly Fleet Capital Corporation) (the
“Lender”). The Loan Agreement has a five-year term, with a maturity
date of June 30, 2008. The Loan Agreement, as amended on August 1,
2005, provides for a $35,000,000 revolving credit facility, which allows Five
Star to borrow based upon a formula of up to 65% of eligible inventory and
85%
of eligible accounts receivable, as defined therein. The interest
rates under the Loan Agreement consist of LIBOR plus a credit spread of 1.5%
(6.87% at June 30, 2007) for borrowings not to exceed $15,000,000 and the prime
rate (8.25% at June 30, 2007) for borrowings in excess of the above mentioned
LIBOR-based borrowings. The credit spreads can be reduced in the
event that Five Star achieves and maintains certain performance
benchmarks. At June 30, 2007 and December 31, 2006, approximately
$24,262,000 and $17,664,000 was outstanding under the Loan Agreement and
approximately $6,054,000 and $2,929,000 was available to be borrowed,
respectively. Substantially all of Five Star’s assets are pledged as
collateral for these borrowings. Under the Loan Agreement Five Star is subject
to covenants requiring minimum net worth, limitations on losses, if any, and
minimum or maximum values for certain financial ratios. As of June
30, 2007, Five Star was in compliance with all required
covenants.
(Continued)
12
NATIONAL
PATENT DEVELOPMENT CORPORATION AND
SUBSIDIARIES
Notes
to
Condensed Consolidated Financial Statements
Three and six months ended June 30, 2007 and 2006
(unaudited)
Three and six months ended June 30, 2007 and 2006
(unaudited)
In
connection with the Loan Agreement, Five Star also entered into a derivative
transaction with the Lender. The derivative transaction is an
interest rate swap and has been designated as a cash flow
hedge. Effective July 1, 2004 through June 30, 2008, Five Star will
pay a fixed interest rate of 3.38% to the Lender on notional principal of
$12,000,000. In return, the Lender will pay to Five Star a floating
rate, namely, LIBOR, on the same notional principal amount. The
credit spread under the new Loan Agreement is not included in, and will be
paid
in addition to this fixed interest rate of 3.38%. The fair value of
the interest rate swap amounted to $241,000 and $320,000 at June 30, 2007 and
December 31, 2006, respectively and is included in other assets in the
accompanying balance sheets.
On
June
17, 2004, Five Star also entered into a derivative interest rate collar
transaction during the period from July 1, 2004 through June 30, 2008, on
notional principal of $12,000,000. The transaction consists of an
interest rate floor of 2.25%, whereas if LIBOR is below 2.25%, the Lender will
pay to Five Star the difference between LIBOR and 2.25%, on the same notional
principal amount. The transaction also consists of an interest rate
cap of 5.75%, whereas if LIBOR is above 5.75%, Five Star will pay to the Lender
the difference between LIBOR and 5.75%, on the same notional principal
amount.
MXL
short-term borrowings
On
March
1, 2005, MXL obtained a Line of Credit Loan (the “MXL Line”) from M&T Bank
with a one year term, maturing on March 1, 2006, which has been extended to
June
30, 2008 on the same terms. The MXL Line provides for a $1,000,000
revolving credit facility, which is secured by MXL’s eligible accounts
receivable, inventory and a secondary claim on the Lancaster, PA property.
On
November 27, 2006 the MXL Line was amended to a $900,000 line of
credit. The interest rates under the MXL Line consist of LIBOR plus a
credit spread of 2.5% or the prime rate. The MXL Line is subject to
an unused commitment fee of 0.125% of the average daily unused balance of the
line payable quarterly. The Company has guaranteed the MXL Line up to
$785,000. At June 30, 2007 and December 31, 2006, $750,000 was
outstanding under the MXL Line and $150,000 was available to be
borrowed. The MXL Line contains certain financial covenants which are
calculated on an annual basis at December 31. As of December 31,
2006, MXL was in compliance with all required covenants.
(Continued)
13
NATIONAL
PATENT DEVELOPMENT CORPORATION AND
SUBSIDIARIES
Notes
to
Condensed Consolidated Financial Statements
Three and six months ended June 30, 2007 and 2006
(unaudited)
Three and six months ended June 30, 2007 and 2006
(unaudited)
8. Inventories
Inventories
are comprised of the following (in thousands):
June
30, 2007
|
December
31, 2006
|
|||||||
Raw
materials
|
$ |
420
|
$ |
393
|
||||
Work
in process
|
370
|
149
|
||||||
Finished
goods
|
26,865
|
21,993
|
||||||
$ |
27,655
|
$ |
22,535
|
9. Investment
in Indevus Pharmaceuticals, Inc.
Indevus
Pharmaceuticals, Inc., a Delaware corporation ("Indevus"), is a
biopharmaceutical company, engages in the acquisition, development, and
commercialization of products to treat urological, gynecological, and men's
health conditions.
Effective
April 18, 2007 (the "Effective Time"), all of the outstanding common stock
of Valera Pharmaceuticals, Inc. (“Valera”) was acquired by Indevus pursuant to
the terms and conditions of an Agreement and Plan of Merger, dated as of
December 11, 2006 (the “Merger Agreement”). Pursuant to the Merger Agreement,
the Company, as a stockholder of Valera through MXL, received 1.1337 shares
of
Indevus common stock for each share of Valera common stock held by the Company
immediately prior to the Effective Time. As a result, at the Effective Time,
the
2,070,670 shares of Valera common stock held by the Company were converted
into
an aggregate of 2,347,518 shares of Indevus common stock. The shares are
currently restricted pursuant to Rule 145 of the Securities Act of 1933, as
amended ("Rule 145"). Such restrictions will generally lapse one year following
the Effective Time. In April 2007, the Company recognized a pre-tax
gain of $14,960,000 on the exchange of shares. The merger was treated as a
tax
free merger under Internal Revenue Code Section 368. In addition, for
each share of Valera common stock held by the Company immediately prior to
the
Effective Time, the Company received one contingent stock right for each of
three Valera product candidates in development - Supprelin-LA, a ureteral stent
and VP003 (Octreotide implant) – that will become convertible into $1.00, $1.00
and $1.50, respectively, worth of Indevus common stock to the extent specific
milestones with respect to each product candidate are achieved. Thus, if all
contingent milestones are achieved, the Company will receive $2,070,670,
$2,070,670 and $3,106,005, respectively, worth of Indevus common stock on the
date the milestone is met, at which date additional gain will be recognized.
On
May 3, 2007 Indevus announced that it had received FDA approval for
Supprelin-LA. Therefore in May 2007, the Company received the first
$2,070,670 worth of Indevus common stock consisting of 291,964 shares, and
recognized an additional pre-tax gain of $2,070,670. The restrictions of
Rule 145 will generally lapse with respect to the Indevus shares prior to June
30, 2008; accordingly, all the Indevus shares are classified as available
for sale securities and measured at fair value with the changes in such value
subsequent to the merger recorded in other comprehensive
income. During the quarter and six months ended June 30, 2007, the
Company sold 291,964 shares of Indevus on the open market, for net proceeds
of
$1,822,000 (settled in July 2007) and realized a loss of $236,000 in Investment
and other income (loss) in the three months ended June 30,
2007.
(Continued)
14
NATIONAL
PATENT DEVELOPMENT CORPORATION AND
SUBSIDIARIES
Notes
to
Condensed Consolidated Financial Statements
Three and six months ended June 30, 2007 and 2006
(unaudited)
Three and six months ended June 30, 2007 and 2006
(unaudited)
At
June
30, 2007, two related parties, Bedford Oak Partners and Mr. Jerome I. Feldman,
are entitled to receive 50% of any profit received from the sale on a pro-rata
basis, of 423,492 shares of Indevus common stock in excess of $3.47 per share,
and 50% of the proceeds from the sale on a pro-rata basis of 56,965 shares
of
Indevus stock. The unrealized gain on Indevus shares available for sale at
June
30, 2007 which would be payable to the related parties upon sale totaled
$845,000, which is included in Accounts payable and accrued expenses at June
30,
2007. In addition $79,000 is payable in connection the Indevus shares sold
subsequent to the merger which is included in Accounts payable and
accrued expenses at June 30, 2007. The increase in the liability
which was $587,000 and $603,000 for quarter and six months ended June 30, 2007,
respectively, is included in Investment and other income (loss) in the Statement
of Operations.
The
gain
on exchange of Valera stock resulted from tax free reorganization and
accordingly was not subject to current income tax. In addition, the
deferred income tax liability attributable to the excess statement basis over
tax basis in Indevus stock received in the exchange was offset by a reduction
of
the deferred tax asset valuation allowance. Accordingly, no provision
for income tax is included in the accompanying Statement of Operations related
to the gain on the exchange.
10. Business
segments
The
operations of the Company currently consist of the following two business
segments, by which the Company is managed.
The
MXL
Segment manufactures precision coated and molded optical plastic products.
MXL
is a specialist in the manufacture of polycarbonate parts requiring adherence
to
strict optical quality specifications, and in the application of abrasion and
fog resistant coatings to those parts.
The
Five
Star Segment distributes paint sundry items, interior and exterior stains,
brushes, rollers, caulking compounds and hardware products on a regional
basis.
(Continued)
15
NATIONAL
PATENT DEVELOPMENT CORPORATION AND
SUBSIDIARIES
Notes
to
Condensed Consolidated Financial Statements
Three and six months ended June 30, 2007 and 2006
(unaudited)
Three and six months ended June 30, 2007 and 2006
(unaudited)
The
following tables set forth the sales and operating income (loss) of each of
the
Company's operating segments (in thousands):
Three
months ended
|
Six
months ended
|
|||||||||||||||
June
30,
|
June
30,
|
|||||||||||||||
2007
|
2006
|
2007
|
2006
|
|||||||||||||
Sales
|
||||||||||||||||
Five
Star
|
$ |
35,927
|
$ |
28,938
|
$ |
65,788
|
$ |
57,890
|
||||||||
MXL
|
2,207
|
2,223
|
4,277
|
4,476
|
||||||||||||
$ |
38,134
|
$ |
31,161
|
$ |
70,065
|
$ |
62,366
|
Three
months ended
|
Six
months ended
|
|||||||||||||||
June
30,
|
June
30,
|
|||||||||||||||
2007
|
2006
|
2007
|
2006
|
|||||||||||||
Segment
operating income (loss)
|
||||||||||||||||
Five
Star
|
$ |
1,419
|
$ |
754
|
$ |
2,557
|
$ |
1,631
|
||||||||
MXL
|
86
|
137
|
(43 | ) |
231
|
|||||||||||
$ |
1,505
|
$ |
891
|
$ |
2,514
|
$ |
1,862
|
A
reconciliation of the segment operating income (loss) to
income (loss) before income tax (expense) benefit and minority
interests in the condensed consolidated statements of operations is shown below
(in thousands):
Three
months ended
|
Six
months ended
|
|||||||||||||||
June
30,
|
June
30,
|
|||||||||||||||
2007
|
2006
|
2007
|
2006
|
|||||||||||||
Segment
operating income
|
$ |
1,505
|
$ |
891
|
$ |
2,514
|
$ |
1,862
|
||||||||
Corporate
and other general and administrative expenses
|
(984 | ) | (429 | ) | (1,604 | ) | (910 | ) | ||||||||
Interest
expense
|
(506 | ) | (465 | ) | (832 | ) | (843 | ) | ||||||||
Gain
on merger of Valera
|
17,031 | 17,031 | ||||||||||||||
Investment
and other income (loss)
|
(835 | ) |
55
|
(769 | ) | (182 | ) | |||||||||
Income
(loss) before income tax
|
||||||||||||||||
expense
and minority interests
|
$ |
16,211
|
$ |
52
|
$ |
16,339
|
$ | (73 | ) |
(Continued)
16
NATIONAL
PATENT DEVELOPMENT CORPORATION AND
SUBSIDIARIES
Notes
to
Condensed Consolidated Financial Statements
Three and six months ended June 30, 2007 and 2006
(unaudited)
Three and six months ended June 30, 2007 and 2006
(unaudited)
11. Related
party transactions
a) On
November 12, 2004, the Company entered into an agreement to borrow approximately
$1,022,000 from Bedford Oak Partners, which is controlled by Harvey P. Eisen,
Chairman, Chief Executive Officer and a director of the Company, and
approximately $568,000 from Jerome I. Feldman, who was at the time Chairman
and
Chief Executive Officer of the Company, which was utilized to exercise an option
held by the Company to purchase Series B Convertible Preferred shares of
Valera. The loans bore interest at 6% per annum, matured on October
31, 2009, and were secured by all shares of Valera owned by the Company,
including the purchased shares. On January 11,
2005, the Company prepaid the loans and all accrued interest in full. As further
consideration for making these loans, Bedford Oak Partners and Mr. Feldman
became entitled to a portion of the consideration received by the Company on
the
sale of certain Valera shares. As a result of the acquisition of
Valera by Indevus (see Note 9) this obligation presently relates to the sale
of
Indevus shares by the Company. Upon such sale, Bedford Oak Partners
and Mr. Feldman are entitled to receive 50% of any amount in excess of $3.47
per
share which is received by the Company upon the sale of 423,492 shares of
Indevus common stock, and 50% of the total proceeds from the sale of an
additional 56,965 shares of Indevus stock (see Note 9).
b) Concurrently
with its spin-off from GPS, the Company and GPS entered into a management
agreement under which certain of the Company’s executive officers who were also
executive officers of GPS were paid by GPS subject to reimbursement by the
Company. Additionally, GPS provided support with respect to corporate federal
and state income taxes, corporate legal services, corporate secretarial
administrative support, and executive management consulting. The term
of the agreement extends through November 24, 2007.
The
fee
paid by the Company under this agreement was $135,000 and $218,000 for the
quarters ended June 30, 2007 and 2006, respectively, and $335,000 and $434,000
for the six months ended June 30, 2007 and 2006, respectively, representing
approximately 80% of the cost of the compensation and benefits required to
be
provided by GPS to Jerome Feldman, who served as the Company’s Chief Executive
Officer until May 31, 2007 (see Note 12(a)). The Company is not, and does not
anticipate, receiving any further material services during the remaining term
of
this agreement.
(Continued)
17
NATIONAL
PATENT DEVELOPMENT CORPORATION AND
SUBSIDIARIES
Notes
to
Condensed Consolidated Financial Statements
Three and six months ended June 30, 2007 and 2006
(unaudited)
Three and six months ended June 30, 2007 and 2006
(unaudited)
12. Stockholders
equity
Changes
in Stockholders’ equity for the six months ended June 30, 2007, are as follows
(in thousands):
Balance,
January 1, 2007
|
$ |
21,137
|
||
Net
income
|
15,188
|
|||
Proceeds
from sale of common stock
|
480
|
|||
Reclassification
adjustment principally for gain on exchange of Valera securities
recognized in merger included in net income
|
(4,614 | ) | ||
Net
unrealized gain (loss) on available-for-sale-securities
|
(618 | ) | ||
Expenses
paid in common stock
|
31
|
|||
Common
stock subject to exchange rights
|
(477 | ) | ||
Purchases
of treasury stock
|
(220 | ) | ||
Equity
based compensation expense
|
75
|
|||
Decrease
in value of interest rate swap, net of tax
|
(28 | ) | ||
Balance,
June 30, 2007
|
$ |
30,954
|
The
following transactions occurred during the six month period ended June 30,
2007:
|
a.
|
On
March 1, 2007, the Company’s Board of Directors determined that effective
upon Jerome Feldman ceasing to serve as Chairman of the Board
and Chief Executive Officer of the Company, Harvey P. Eisen, who
at the
time served only as a director of the Company, would serve as Chairman
of
the Board and Chief Executive Officer of the Company, and that effective
upon the commencement of his service as Chairman of the Board and
Chief
Executive Officer of the Company, Mr. Eisen would receive an annual
salary
of $100,000. Mr. Feldman's employment agreement expired on May 31,
2007.
In addition, the Company’s Board of Directors granted to Mr. Eisen options
to purchase an aggregate of 2,500,000 shares of the Company’s common
stock, 2,250,000 of which are subject to shareholder approval of
an
amendment to the Company’s 2003 Plan, at an exercise price equal to $2.45
per share, which was the average of the closing bid and asked prices
of
the Company’s common stock on March 1, 2007. The options are to vest in
three equal annual installments, commencing on March 1, 2008 provided
that
Mr. Eisen continues to be an employee of the Company. At
March 31, 2007, the Company recognized 250,000 shares as granted
and
2,250,000 shares as subject to shareholder
approval.
|
(Continued)
18
NATIONAL
PATENT DEVELOPMENT CORPORATION AND
SUBSIDIARIES
Notes
to
Condensed Consolidated Financial Statements
Three and six months ended June 30, 2007 and 2006
(unaudited)
Three and six months ended June 30, 2007 and 2006
(unaudited)
|
b.
|
On
March 1, 2007, John C. Belknap was elected as a director of Five
Star. Mr. Belknap was also elected to serve as President and
Chief Executive Officer of Five Star. Mr. Belknap has served as a
director
of the Company since October 20, 2006 and has been an employee of
the
Company since December 1, 2006.
|
Mr.
Belknap was granted 1,000,000 restricted shares of Five Star Common Stock (see
Note 4). In addition, Mr. Belknap was granted options to purchase an aggregate
of 400,000 shares of the Company’s common stock, 181,240 of which are subject to
shareholder approval of an amendment to the Company’s 2003 Incentive Stock Plan,
at an exercise price equal to $2.45 per share, which was the average of the
closing bid and asked prices of the Company’s common stock on March 1,
2007. Contingent upon Mr. Belknap’s continued employment with the
Company, the options will vest in three equal annual installments, commencing
on
December 1, 2007. At March 31, 2007, the Company recognized options
to buy 218,760 shares as granted and recognized a charge of $ 20,000 and $26,000
during the quarter and six months ended June 30, 2007,
respectively. Options to buy 181,240 shares subject to shareholder
approval will be valued on the day such approval is obtained.
|
c.
|
Mr.
S. Leslie Flegel was named a Director of the Company on March 2,
2007 and
on March 1, 2007 was appointed as Chairman and elected as a director
of
Five Star. Effective March 2, 2007, Mr. Flegel entered into a
three-year agreement with Five Star ending on March 1, 2010 (the
"FS
Agreement") which provides for an annual fee of $100,000 and reimbursement
(i) for all travel expenses incurred in connection with his performance
of
services for Five Star and (ii) beginning in November 2007, for up
to
$125,000 per year of the cost of maintaining an office. In addition,
pursuant to the FS Agreement, Mr. Flegel was issued 2,000,000 shares
of
Five Star common stock, all of which are fully vested and not subject
to
forfeiture. The 2,000,000 shares were valued at $720,000 based
on the closing price of Five Star’s common stock on March 2, 2007. Such
amount is to be charged to compensation expense over the term of
the FS
Agreement. In addition, the Company recognized a gain of $1,000 on
the
reduction in ownership interest of Five Star at the time of
issuance. The issuance of the Five Star shares reduced the
Company’s ownership of Five Star from 66% to
58%.
|
On
March
2, 2007, the Company and Mr. Flegel entered into an agreement pursuant to which
the Company sold Mr. Flegel 200,000 shares of the Company’s common stock at a
price of $2.40 per share or $480,000. Mr. Flegel has the right to exchange
any
or all of the 200,000 shares of the Company’s common stock into shares of Five
Star common stock held by the Company at the fixed rate of six shares of Five
Star common stock for each share of the Company’s common stock. The value of the
option to convert the Company’s stock held by Mr. Flegel into shares of Five
Star has been valued using a Black-Scholes formula and recognized as
compensation expense by Five Star over the three year term of the FS Agreement.
In addition, as the exchange rights if exercised would require the Company
to
effectively surrender net assets to redeem common stock, the Company accounted
for the issuance of the 200,000 shares as temporary equity at an amount
equivalent to the carrying value of Five Star’s equity that could be acquired by
the holder of such shares.
(Continued)
19
NATIONAL
PATENT DEVELOPMENT CORPORATION AND
SUBSIDIARIES
Notes
to
Condensed Consolidated Financial Statements
Three and six months ended June 30, 2007 and 2006
(unaudited)
Three and six months ended June 30, 2007 and 2006
(unaudited)
|
d.
|
On
March 2, 2007 the Company amended a $2,800,000 Promissory Note due
from
Five Star (eliminated in consolidation). Under the terms of the
amended Promissory Note, the term of the Promissory Note has been
extended
from June 30, 2007 to June 30, 2009 at an interest rate of 9% per
annum. In addition, the Promissory Note and any unpaid accrued
interest is convertible, in whole or in part, at the Company’s
option into shares of Five Star common stock at a price
of $.40 per share, subject to anti-dilution adjustment. Five
Star does not have the right to prepay the Promissory Note prior
to
maturity.
|
13. Acquisition
of Right-Way Dealer Warehouse
On
April
5, 2007, Five Star acquired substantially all the assets (except "Excluded
Assets" as defined) and assumed the Assumed Liabilities (as defined) of
Right-Way Dealer Warehouse, Inc. ("Right-Way") pursuant to the terms of a
definitive asset purchase agreement, dated as of March 13, 2007 (the
"Agreement"), with Right-Way for approximately $3,200,000 in cash and the
assumption of liabilities in the approximate amount of $50,000. Transaction
costs of approximately $200,000 were incurred by Five Star. The assets consisted
primarily of approximately $1,186,000 of accounts receivable at fair value
and
approximately $2,213,000 of inventory at fair value. The acquisition included
all of Right-Way's Brooklyn Cash & Carry business and
operations. Five Star acquired the assets of Right-Way in order to
increase its presence and market share in its current geographic
area.
Upon
closing of the transaction, Five Star leased a warehouse at which the Brooklyn
Cash & Carry business is conducted from an affiliate of the principal of
Right-Way, with an option to purchase the warehouse, and a wholly-owned
subsidiary of Five Star also entered into an employment agreement with Ronald
Kampner, the principal of Right-Way to serve as Senior Vice President of Sales
for Five Star. The employment agreement provides for a three-year
term (subject to earlier termination), the payment of a base salary of $200,000
per annum, and cash incentive compensation as described in the employment
agreement. In addition, Mr. Kampner was granted an option covering 200,000
shares of Five Star Products, Inc. common stock (see Note 4).
The
results of operations of Right-Way are included in the consolidated financial
statements from the date of acquisition. The following unaudited pro
forma consolidated amounts give effect to the acquisition of the Right-Way
as if
it had occurred on January 1, 2006. Right-Way had filed for reorganization
under
Chapter XI of the Bankruptcy Act prior to the acquisition by Five
Star.
The
pro
forma results of operations have been prepared for comparative purposes only
and
are not necessarily indicative of the operating results that would have been
achieved had the acquisitions been consummated as of the above date, nor are
they necessarily indicative of future operating results.
(in
thousands, except per share data)
Six months
ended June 30,
|
Three
months ended
|
|||||||||||
2007
|
2006
|
June
30, 2006
|
||||||||||
Sales
|
$ |
74,399
|
$ |
84,550
|
$ |
42,847
|
||||||
Net
income (loss)
|
14,458
|
(456 | ) |
99
|
||||||||
Earnings
(loss) per share, basic and diluted
|
$ |
.81
|
$ | (.03 | ) | $ |
.01
|
(Continued)
20
NATIONAL
PATENT DEVELOPMENT CORPORATION AND SUBSIDIARIES
Item
2.
|
Management’s
Discussion and Analysis of Financial Condition and Results of
Operations
|
Cautionary
Statement Regarding Forward-Looking Statements
This
report contains forward-looking statements within the meaning of Section 27A
of
the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”). The Private
Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward
looking statements. Forward-looking statements are not statements of historical
facts, but rather reflect our current expectations concerning future events
and
results. We use words such as “expects”, “intends”, “believes”, “may”, “will”
and “anticipates” to indicate forward-looking statements.
Factors
that may cause actual results to differ from those results expressed or implied,
include, but are not limited to, those listed under “Risk Factors” in our Annual
Reports on Form 10-K filed with the Securities and Exchange Commission (the
“SEC”); an unexpected decline in revenue and/or net income derived by the
Company’s wholly-owned subsidiary, MXL Industries, Inc. (“MXL”), or by our
majority-owned subsidiary, Five Star Products, Inc. (“Five Star”), due to the
loss of business from significant customers or otherwise. In addition, MXL
is
dependant on the availability and pricing of plastic resin, principally
polycarbonate, and Five Star is subject to the intense competition in the
do-it-yourself industry.
Because
these forward-looking statements involve risks and uncertainties, there are
important factors that could cause actual results to differ materially from
those expressed or implied by these forward-looking statements, including,
but
not limited to, those factors set forth under “Risk Factors” in our Annual
Reports on Form 10-K and those other risks and uncertainties detailed in other
periodic reports and registration statements that we file with the SEC from
time
to time. We caution that these risk factors may not be exhaustive. We operate
in
a continually changing business environment, and new risk factors emerge from
time to time. We cannot predict these new risk factors, nor can we assess the
effect, if any, of the new risk factors on our business or the extent to which
any factor or combination of factors may cause actual results to differ from
those expressed or implied by these forward-looking statements.
If
any
one or more of these expectations and assumptions proves incorrect, actual
results will likely differ materially from those contemplated by the
forward-looking statements. Even if all of the foregoing assumptions and
expectations prove correct, actual results may still differ materially from
those expressed in the forward-looking statements as a result of factors we
may
not anticipate or that may be beyond our control. While we cannot assess the
future impact that any of these differences could have on our business,
financial condition, results of operations and cash flows or the market price
of
shares of our common stock, the differences could be significant. We do not
undertake to update any forward-looking statements made by us, whether as a
result of new information, future events or otherwise. You are cautioned not
to
unduly rely on such forward-looking statements when evaluating the information
presented in this report.
21
General
Overview
The
Company was incorporated on March 10, 1998 as a wholly-owned subsidiary of
GP
Strategies Corporation. On February 12, 2004, the Company was
recapitalized whereby the authorized capital was changed to 10,000,000 shares
of
preferred stock and 30,000,000 shares of common stock. On July 30,
2004 GP Strategies transferred to the Company its optical plastics business
through its wholly-owned subsidiary, MXL; the home improvement distribution
business through its partially owned subsidiary Five Star; and certain other
non-core assets. The separation of these businesses was accomplished
through a pro-rata distribution (the “Distribution” or “Spin-off”) of 100% of
the outstanding common stock of the Company to the stockholders of GP Strategies
on November 18, 2004, the record date for the Distribution. On
November 24, 2004, holders of record received one share of the Company’s common
stock for each share of GP Strategies common stock or Class B capital stock
owned.
The
Company operates in two segments: MXL and Five Star. The Company also
owns certain other non-core assets, including an investment in a publicly held
company, Millennium Cell; an approximately 3% interest in a publicly held
company, Indevus Pharmaceuticals, Inc. (see Note 9 to the Condensed Consolidated
Financial Statements); and certain real estate in Pawling, NY and Killingly,
CT. The Company monitors Millennium Cell for progress in the
commercialization of Millennium Cell’s emerging technology and monitors Indevus
for progress in achieving certain milestones and their marketing
efforts. In the quarter ended June 30, 2007 the Company sold 291,964
shares of Indevus stock and has continued to sell shares (445,000) in the
subsequent period.
MXL
Overview
The
primary business of MXL is the manufacture of polycarbonate parts requiring
adherence to strict optical quality specifications, and the application of
abrasion and fog resistant coatings to those parts. MXL also designs
and constructs injection molds for a variety of applications. Some of
the products that MXL produces include:
|
·
|
facemasks
and shields for recreation purposes and industrial safety
companies,
|
|
·
|
precision
optical systems, including medical optics, military eye wear and
custom
molded and decorated products, and
|
|
·
|
tools,
including optical injection mold tools and standard injection mold
tools.
|
MXL’s
manufactures and sells its products to various commercial and government
customers, who utilize MXL’s parts to manufacture products that will be
ultimately delivered to the end-user. MXL’s government customers
include various offices of the Department of Defense, while MXL’s commercial
customers are primarily in the recreation, safety, and security industries.
Some
of MXL’s consumer based products are considered to be at the high-end of their
respective markets. As a result, sales of MXL’s products may
decline together with a decline in discretionary consumer spending; therefore
a
key performance indicator that the Company’s management uses to manage the
business is the level of discretionary spending in key markets, specifically
the
United States and Japan. Other key performance measures used by the
Company’s management to run the business include:
22
|
·
|
consumer
confidence indices in key markets,
|
|
·
|
sales
levels of complementary items in the recreational vehicle market,
such as
motorcycles, RV’s and snowmobiles,
|
|
·
|
levels
of defense spending, and
|
|
·
|
new
OSHA safety standards.
|
MXL
believes that the principal strengths of its business are its state-of-the-art
injection molding equipment, advanced production technology, high quality
standards, and on time deliveries. However, due to the focused nature
of the market, MXL has a limited customer base and tends to be adversely
affected by a loss in business from its significant customers.
Five
Star Overview
Five
Star
is a publicly held company that is a distributor in the United States of home
decorating, hardware, and finishing products. Five Star offers
products from leading manufacturers in the home improvement industry and
distributes those products to retail dealers, which include lumber yards, “do-it
yourself” centers, hardware stores and paint stores. Five Star has
grown to be one of the largest independent distributors in the Northeast United
States by providing a complete line of competitively priced products, timely
delivery and attractive pricing and financing terms to its
customers.
The
following key factors affect Five Star’s financial and operational
performance:
|
·
|
its
ability to negotiate the lowest prices from its
suppliers,
|
|
·
|
its
ability to increase revenue by obtaining new customers, while maintaining
a level fixed cost structure by utilizing its existing
warehouses,
|
|
·
|
the
housing market in general,
|
|
·
|
consumers’
confidence in the economy,
|
|
·
|
consumers’
willingness to invest in their homes,
and
|
|
·
|
weather
conditions that are conducive to home improvement
projects.
|
The
following key performance measures are utilized by the Company’s management to
run Five Star’s business:
|
·
|
new
U.S. housing starts,
|
|
·
|
sales
of existing homes,
|
23
|
·
|
purchases
from each vendor, and
|
|
·
|
performance
benchmarks used by Home Depot and Lowe’s, such as number of stores and
square footage, as well as financial
benchmarks.
|
Five
Star
operates in the Home Improvement market, which has grown in recent years and
for
which the National Retail Hardware Association predicts average annual
industry growth of approximately 5.7% for the next several
years. Nonetheless, Five Star faces intense competition from large
national distributors, smaller regional distributors, and manufacturers that
bypass the distributor and sell directly to the retail outlet. The
principal means of competition for Five Star are its strategically placed
distribution centers and its extensive inventory of quality, name-brand
products. In addition, Five Star’s customers face stiff competition
from Home Depot and Lowe’s, which purchase directly from manufacturers.
Management of Five Star believes that the independent retailers that are Five
Star’s customers remain a viable alternative to Home Depot and Lowe’s, due to
the shopping preferences of and the retailer’s geographic convenience for some
consumers.
On
April
5, 2007, Five Star acquired substantially all the assets (except "Excluded
Assets" as defined) and assumed the Assumed Liabilities (as defined) of
Right-Way Dealer Warehouse, Inc. ("Right-Way") pursuant to the terms of a
definitive asset purchase agreement, dated as of March 13, 2007 (the
"Agreement"), with Right-Way for approximately $3,200,000 in cash and the
assumption of liabilities in the approximate amount of $50,000. The assets
consisted primarily of approximately $1,186,000 of accounts receivable at fair
value and approximately $2,213,000 of inventory at fair value. The acquisition
included all of Right-Way's Brooklyn Cash & Carry business and operations
which sells paint sundry and hardware supplies to local retail
stores.
Upon
closing of the transaction, Five Star leased a warehouse at which the Brooklyn
Cash & Carry business is conducted from an affiliate of the principal of
Right-Way, with an option to purchase the warehouse, and a wholly-owned
subsidiary of Five Star also entered into an employment agreement with Ronald
Kampner, the principal of Right-Way to serve as Senior Vice President of Sales
for Five Star Group. The employment agreement provides for a
three-year term (subject to earlier termination), the payment of a base salary
of $200,000 per annum, and cash incentive compensation as described in the
employment agreement. In addition, Mr. Kampner was granted an option for 200,000
shares of Five Star Products, Inc. common stock under the 2007 Five Star Plan,
which is subject to the approval of stockholders of Five Star. The options
will
vest if Five Star meets certain EBITDA targets over the next three years
provided that Mr. Kampner continues to be employed by Five Star
Group.
To
further expand, Five Star is considering strategies intended to grow its revenue
base in the Northeast and Mid-Atlantic States through internal initiatives
and
to acquire complementary distributors outside its current geographic
area. There is no assurance that these growth plans can be executed
and, if executed, will be successful from an operational or financial
standpoint. These plans could require capital beyond the funds
presently available to Five Star.
24
Operating
Highlights
Three
months ended June 30, 2007 compared to the three months ended June 30,
2006
For
the
three months ended June 30, 2007, the Company had income before income tax
expense and minority interest of $16,211,000 compared to income before income
tax expense and minority interest of $52,000 for the three months ended June
30,
2006. The increase in pre-tax income is primarily the result of the
following: (i) a net gain of $17,031,000 recognized on the merger of Valera
and Indevus (see Note 9 to the Condensed Consolidated Financial Statements);
(ii) increased segment operating income of $614,000, which is
comprised of a $665,000 increase in operating income for Five Star and a $51,000
decrease in operating income for MXL; (iii) increased selling, general and
administrative expenses at the corporate level of $555,000; and (iv)
a realized loss of $316,000 on the sale of 291,964 Indevus shares in June
2007.
Sales
Three
months
ended
June 30,
|
||||||||
2007
|
2006
|
|||||||
Five
Star
|
$ |
35,927,000
|
$ |
28,938,000
|
||||
MXL
|
2,207,000
|
2,223,000
|
||||||
$ |
38,134,000
|
$ |
31,161,000
|
The
increase in Five Star sales of $6,989,000 was partially the result of $1,440,000
of sales attributed to the Right-Way Brooklyn Cash and Carry facility, as well
as an overall increase in business within the Connecticut and New Jersey- New
York regions due to the increase in business from Right-Way’s customer base, as
well as an overall increase in business from the traditional customer
base.
Gross
margin
Three
months ended
|
||||||||||||||||
June
30,
|
||||||||||||||||
2007
|
%
|
2006
|
%
|
|||||||||||||
Five
Star
|
$ |
6,255,000
|
17.4
|
$ |
4,915,000
|
17.0
|
||||||||||
MXL
|
535,000
|
24.2
|
619,000
|
27.8
|
||||||||||||
$ |
6,790,000
|
17.8
|
$ |
5,534,000
|
17.8
|
Five
Star’s gross margin of $6,255,000, or 17.4% of net sales, for the quarter ended
June 30, 2007 increased by $1,340,000, when compared to $4,915,000, or 17%
of
net sales, for the quarter ended June 30, 2006. The increase in gross margin
dollars for the quarter ended June 30, 2007 was a result of increased sales
and
the increased gross margin percentage. The gross margin percentage
increased due to increased vendor rebates earned in the period, partially offset
by reduced margins earned on the sale of Cabot exterior stain
products.
25
MXL’s
gross margin of $535,000, or 24.2% of sales, for the quarter ended June 30,
2005
decreased by $84,000 when compared to gross profit of $619,000, or 27.8% of
sales, for the quarter ended June 30, 2005, mainly due to the following: (i)
reduced margin dollars and reduced gross margin percentage due to the completion
of the closing of the Illinois facility during the quarter ended June 30,
2007; (ii) reduced gross margin percentage due to change in product mix; and
(iii) increased costs for labor and the related benefits.
Selling,
general, and administrative expenses
For
the
three months ended June 30, 2007, selling, general and administrative expenses
increased by $1,197,000 from $5,073,000 for the three months ended June 30,
2006
to $6,269,000 partially due to the following: (i) increased general and
administrative expenses of $555,000 at the corporate level primarily due to
increased professional fees and personnel expenses; and (ii) increased selling,
general and administrative expenses at Five Star of $707,000
primarily attributable to the following: (a) increased delivery expense and
sales commissions due to increased sales, (b) increased general and
administrative expenses primarily related to the acquisition of Right-Way,
(c)
increased professional fees, and (d) partially offset by increased vendor
marketing allowances recognized in the periods. The Company expects that
selling, general and administrative expenses at the corporate level will remain
relatively constant through out the rest of 2007 based upon the current
operations of the Company.
Gain
on exchange of Valera for Indevus shares
For
the
quarter ended June 30, 2007 the Company recognized a gain of $17,031,000
recognized as a result of the merger of Valera Pharmaceuticals, Inc., in which
the Company had an approximately 14% interest and Indevus Pharmaceuticals,
Inc.,
in which the Company has an approximately 3% interest. The gain includes the
receipt of the first of three contingent tranches of consideration, valued
at
$2,070,000 received in May 2007. The Merger Agreement between Valera and Indevus
was treated as a tax free merger under Internal Revenue Code Section
368.
Investment
and other income (loss), net
The
Company recognized investment and other income (loss) of ($835,000) for the
three months ended June 30, 2007, compared to $55,000 for the three months
ended
June 30, 2006. Investment and other income, net includes
interest income, investment income, and recognition of a gain or loss for the
change in the fair value of the Five Star’s interest rate collar. The
loss is primarily attributable to a charge of $587,000 representing the
unrealized profit which would be paid to related parties upon sale of Indevus
available for sale shares in 2007, compared to a gain of $12,000 in 2006, as
well as the change in the fair value of Five Star’s interest rate collar and the
loss of $236,000 on the sale of approximately 11% (291,964 shares) of the
Company’s Indevus common stock in June 2007.
26
Income
taxes
For
the
three months ended June 30, 2007 and 2006, the Company recorded an income tax
expense of $355,000 and of $125,000, respectively, which represents the
Company’s applicable federal, state and local tax expense for the
periods. The provision for income taxes differs from the tax computed
at the federal statutory income tax rate due primarily to recording income
tax
expense on the income of Five Star, a 58% owned subsidiary, which is not
included in the Company’s consolidated return. The gain on exchange of Valera
stock resulted from a tax free reorganization and accordingly was not
subject to current income tax. In addition, the deferred income tax
liability attributable to the excess statement basis over tax basis in Indevus
stock received in the exchange was offset by a reduction of the deferred tax
asset valuation allowance. Accordingly, no provision for income tax
is included in the accompanying Statement of Operations related to the gain
on
the exchange.
Six
months ended June 30, 2007 compared to the six months ended June 30,
2006
For
the
six months ended June 30, 2007 the Company had income before income tax expense
and minority interest of $16,339,000 compared to a loss before income tax
expense and minority interest of $73,000 for the six months ended June 30,
2006. The increase in pre-tax income is primarily a result of the
following: (i) a net gain of $17,031,000 recognized on the merger
of Valera and Indevus (see Note 9 to the Condensed Consolidated
Financial Statements); (ii) increased segment operating income of
$652,000 which is comprised of a $926,000 increase in operating income for
Five
Star and a $274,000 decrease in operating income (loss) for MXL; and (iii)
increased selling , general and administrative expenses at the corporate level
of $694,000 and a realized loss of $316,000 on the sale of 291,964
Indevus shares in June 2007.
Sales
Six
months ended
June
30,
|
||||||||
2007
|
2006
|
|||||||
Five
Star
|
$ |
65,788,000
|
$ |
57,890,000
|
||||
MXL
|
4,277,000
|
4,476,000
|
||||||
$ |
70,065,000
|
$ |
62,366,000
|
The
increase in Five Star sales of $7,898,000 was partially a result of $1,440,000
of sales attributed to the Right-Way Brooklyn Cash and Carry facility, as well
as an overall increase in business within the Connecticut and New Jersey- New
York regions due to the increase in business from Right-Way’s customer base as
well as an overall increase in business from Five Star’s traditional customer
base.
27
The
decrease in MXL sales of $199,000 was primarily a result of the commencement
of
the closing of MXL’s tooling facility in Illinois at the beginning of
2007. MXL decided to close the facility due to losses incurred at the
facility and the decision to outsource its tooling operation. The facility
closed in April 2007.
Gross
margin
Six
months ended
|
||||||||||||||||
June
30,
|
||||||||||||||||
2007
|
%
|
2006
|
%
|
|||||||||||||
Five
Star
|
$ |
10,983,000
|
16.7
|
$ |
9,520,000
|
16.4
|
||||||||||
MXL
|
897,000
|
21.0
|
1,227,000
|
27.4
|
||||||||||||
$ |
11,880,000
|
17.0
|
$ |
10,747,000
|
17.2
|
Five
Star’s gross margin of $10,983,000, or 16.7% of net sales, for the six months
ended June 30, 2007 increased by $1,463,000 when compared to $9,520,000, or
16.4% of net sales, for the six months ended June 30, 2006. The increased gross
margin amount for the six months ended June 30, 2007 was primarily the result
of
increased sales and the increased gross margin percentage. The gross
margin percentage increased due to increased vendor rebates earned in the
period, partially offset by reduced margins earned on the sale of Cabot exterior
stain products.
MXL’s
gross margin of $897,000 or 21% of sales, for the six months ended June 30,
2007
decreased by $330,000 when compared to gross margin of $1,227,000, or 27.4%
of
sales, for the six months ended June 30, 2006, mainly due to the
following: (i) reduced margin dollars of approximately, $170,000 and
reduced gross margin percentage due to the completion of the closing of
the Illinois facility during the quarter ended June 30, 2007; (ii)
reduced gross margin percentage due to change in product; and (iii) increased
costs for labor and the related benefits.
Selling,
general, and administrative expenses
For
the
six months ended June 30, 2007, selling, general and administrative expenses
increased by $1,176,000 from $9,795,000 for the six months ended June 30, 2006
to $10,971,000 due to the following: (i) increased selling, general and
administrative expenses at Five Star of $634,000 due to (a) increased delivery
expense and sales commissions as a result of increased sales, (b) increased
general and administrative expenses primarily related to the acquisition of
Right-Way and (c) increased professional fees, (d) partially offset by increased
vendor marketing allowances recognized in the periods, and (ii) increased
general and administrative expenses at the corporate level of $694,000 primarily
due to increased professional fees and personnel related costs. The
Company expects that selling, general and administrative expenses at the
corporate level will remain relatively constant through out
the rest 0f 2007 based upon the current operations of the
Company.
28
Gain
on exchange of Valera for Indevus shares
For
the
six months ended June 30, 2007 the Company recognized a gain of $17,031,000
recognized as a result of the merger of Valera Pharmaceuticals, Inc., in which
the Company had an approximately 14% interest and Indevus Pharmaceuticals,
Inc.,
in which the Company has an approximately 3% interest. The gain includes the
receipt of the first of three contingent tranches of consideration, valued
at
$2,070,000 received in May 2007. The Merger Agreement between Valera and Indevus
was treated as a tax free merger under Internal Revenue Code Section
368.
Investment
and other income (loss), net
The
Company recognized investment and other income (loss) of ($769,000) for the
six
months ended June 30, 2007 as compared to a loss of ($182,000) the six months
ended June 30, 2065. The change in 2007 is attributable to a $259,000 expense
representing the unrealized profit which would be paid to related parties upon
sale of Valera (Indevus) available for sale shares during the six months ended
June 30, 2006, as compared to a $603,000 expense in the six months ended June
30, 2007 and a realized loss of $236,000 on the sale of 291,964 Indevus shares
in June 2007.
Income
taxes
For
the
six months ended June 30, 2007 and 2006, the Company recorded an income tax
expense of $715,000, and $346,000, respectively, which represents the Company’s
applicable federal, state and local tax expense for the periods. The
provision for income taxes differs from the tax computed at the federal
statutory income tax rate primarily due to recording income tax expense on
the
income of Five Star, a 58% owned subsidiary, which is not included in the
Company’s consolidated return. The gain on exchange of Valera stock resulted
from tax free reorganization and accordingly was not subject to current income
tax. In addition, the deferred income tax liability attributable to
the excess statement basis over tax basis in Indevus stock received in the
exchange was offset by a reduction of the deferred tax asset valuation
allowance. Accordingly, no provision for income tax is included in
the accompanying Statement of Operations related to the gain on the
exchange.
Financial
condition
The
increase in inventory, accounts receivables and accounts payable are the result
of increases at Five Star as a result of the Right-Way cash and carry business,
increased sales volume and seasonal fluctuations.
29
Liquidity
and capital resources
At
June
30, 2007, the Company had cash and cash equivalents of
$4,062,000. The Company believes that cash anticipated to be
generated from operations and borrowing availability under existing credit
agreements will be sufficient to fund the Company’s working capital requirements
for at least the next twelve months.
At
June
30, 2007, the Company had $3,984,000 of cash at the corporate
level. In addition, in the subsequent period, the Company received
approximately $2,650,000 of cash related to the sales of Indevus stock, net
of
expenses and an additional approximately $2,850,000, net in the subsequent
period. In addition, Five Star is restricted from either upstreaming cash to
or
receiving cash from the Company under the terms of their Loan and Security
Agreement. As of June 30, 2007, Five Star is permitted to pay dividends under
the Loan Agreement in an orderly and regular manner and to the extent
permitted by Delaware law.
For
the
six months ended June 30, 2007, the Company’s working capital increased by
$16,423,000 to $28,361,000 from $12,182,000 as of December 31,
2006. The working capital increase was primarily a result of the
reclassification of the Company’s Investment in Indevus, which is $15,799,000 to
Current assets, as well as increased accounts receivable and inventory,
partially offset by increased short term borrowings and accounts
payables.
The
decrease in cash and cash equivalents of $423,000 for the six months ended
June
30, 2007 resulted from the following: (i) net cash used in operations of
$3,596,000, due primarily to an increase in inventory of $5,195,000,
an increase in accounts receivable of $10,227,000, partially offset by an
increase in accounts payable and accrued expenses of $6,981,000; (ii) net cash
used in investing activities of $4,029,000 consisting of $3,399,000
related to the purchase of substantially all the assets of Right-Way, as well
as additions to property, plant and equipment of $849,000 partially
offset by repayment of a receivable from GP Strategies of $325,000, and (iii)
net cash provided by financing activities of $7,202,000, consisting of proceeds
of short term borrowings of $6,598,000, proceeds from long-term debt of
$344,000, partially offset by purchases of treasury stock of
$220,000.
In
2003,
Five Star obtained a Loan and Security Agreement (the “Loan Agreement”) with
Bank of America Business Capital (formerly Fleet Capital Corporation) (the
“Lender”). The Loan Agreement has a five-year term, with a maturity
date of June 30, 2008. The Loan Agreement, as amended in August 1,
2005 provides for a $35,000,000 revolving credit facility, which allows Five
Star to borrow based upon a formula of up to 65% of eligible inventory and
85%
of eligible accounts receivable, as defined therein. The interest
rates under the Loan Agreement consist of LIBOR plus a credit spread of 1.5%
(6.87% at June 30, 2007) for borrowings not to exceed $15,000,000 and the prime
rate (8.25% at June 30, 2007) for borrowings in excess of the above-mentioned
LIBOR-based borrowings. The credit spreads can be reduced in the
event that Five Star achieves and maintains certain performance
benchmarks. At June 30, 2007 and December 31, 2006, approximately
$24,262,000 and $17,664,000 was outstanding under the Loan Agreement and
approximately $6,054,000 and $2,929,000 was available to be borrowed,
respectively. Substantially all of Five Star’s assets are pledged as
collateral for these borrowings. Under the Loan Agreement Five Star is subject
to covenants requiring minimum net worth, limitations on losses, if any, and
minimum or maximum values for certain financial ratios.
30
As
of June 30, 2007 Five Star was in compliance with all
required covenants. The following table sets forth the significant debt
covenants at June 30, 2007:
Covenant
|
Required
|
Calculated
|
Minimum
tangible net worth
|
$6,000,000
|
$9,184,000
|
Debt
to tangible net worth
|
<
6
|
2.64
|
Fixed
charge coverage
|
>1.1
|
1.90
|
Quarterly
income
|
No
loss in consecutive
quarters |
$423,000
–first quarter
income $556,000- second quarter income |
On
March
1, 2005, MXL obtained a Line of Credit Loan (the “MXL Line”) from M&T Bank
with a one year term, maturing on March 1, 2006, which has been extended to
June
30, 2008 on the same terms. The MXL Line provides for a $1,000,000
revolving credit facility, which is secured by MXL’s eligible accounts
receivable, inventory and a secondary claim on the Lancaster, PA
property. The interest rates under the MXL Line consist of LIBOR plus
a credit spread of 3% or the prime rate plus a credit spread of
0.25%. The MXL Line is subject to an unused commitment fee of 0.25%
of the average daily unused balance of the line payable
quarterly. The Company has guaranteed the MXL
Line. At June 30, 2007, $750,000 was outstanding under the MXL
Line and $150,000 was available to be borrowed. The MXL Line contains
certain financial covenants, most significant being a cash flow coverage ratio
of 1.25 to 1.00, which is calculated at December 31 of each year. As of December
31, 2006, MXL was in compliance with its covenants.
Management
discussion of critical accounting policies
The
preparation of our financial statements in conformity with accounting principles
generally accepted in the United States of America requires us to make estimates
and assumptions that affect the reported amounts of assets and liabilities
and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting period. Our estimates, judgments and assumptions are
continually evaluated based on available information and
experience. Because of the use of estimates inherent in the financial
reporting process, actual results could differ from those
estimates.
31
Certain
of our accounting policies require higher degrees of judgment than others in
their application. These include valuation of accounts receivable,
accounting for investments, and impairment of long-lived assets which are
summarized below.
Revenue
recognition
Revenue
on product sales is recognized at the point in time when the product has been
shipped, title and risk of loss has been transferred to the customer, and the
following conditions are met: persuasive evidence of an arrangement exists,
the
price is fixed and determinable, and collectibility of the resulting receivable
is reasonably assured. Allowances for estimated returns and
allowances are recognized when sales are recorded.
Valuation
of accounts receivable
Provisions
for allowance for doubtful accounts are made based on historical loss experience
adjusted for specific credit risks. Measurement of such losses
requires consideration of National Patent Development’s historical loss
experience, judgments about customer credit risk, and the need to adjust for
current economic conditions. The allowance for doubtful accounts as a
percentage of total gross trade receivables was
2.2%
and
4.5% at June 30, 2007 and December 31, 2006, respectively.
Impairment
of long-lived tangible assets
Impairment
of long-lived tangible assets with finite lives results in a charge to
operations whenever events or changes in circumstances indicate that the
carrying amount of an asset may not be recoverable. Recoverability of
long-lived tangible assets to be held and used is measured by a comparison
of
the carrying amount of the asset to future undiscounted net cash flows expected
to be generated by the asset. If such assets are considered to be
impaired, the impairment to be recognized is measured by determining the amount
by which the carrying amount of the assets exceeds the fair value of the
asset. Assets to be disposed of are reported at the lower of their
carrying amount or fair value less cost of sale.
The
measurement of the future net cash flows to be generated is subject to
management’s reasonable expectations with respect to the Company’s future
operations and future economic conditions which may affect those cash
flows.
As
of
June 30, 2007, the Company holds undeveloped land in Pawling, New York with
a
carrying amount of approximately $2.5 million and in East Killingly, Connecticut
with a carrying amount of approximately $0.4 million, which management believes
is less than its fair value, less cost of sale.
Accounting
for investments
The
Company’s investment in marketable securities are classified as
available-for-sale and recorded at their market value with unrealized gains
and
losses recorded as a separate component of stockholders’ equity. A
decline in market value of any available-for-sale security below cost that
is
deemed to be other than temporary, results in an impairment loss, which is
charged to earnings.
32
Determination
of whether an investment is impaired and whether an impairment is other than
temporary requires management to evaluate evidence as to whether an investment’s
carrying amount is recoverable within a reasonable period of time considering
factors which include the length of time that an investment’s market value is
below its carrying amount and the ability of the investee to sustain an earnings
capacity that would justify the carrying amount of the investment.
Income
taxes
To
arrive
at our income tax provision and other tax balances, significant judgment
is
required. In the ordinary course of our business, there are many transactions
and calculations where the ultimate tax outcome is uncertain. Some of these
uncertainties arise as a consequence of the treatment of capital assets,
financing transactions and multistate taxation of
operations. Although we believe that our estimates are reasonable, no
assurance can be given that the final tax outcome of these matters will not
be
different than that which is reflected in our historical tax provisions and
accruals. Such differences could have a material impact on our income tax
provision, other tax accounts and net income in the period in which such
determination is made.
The
Company records a valuation allowance against deferred income tax assets when
management believes it is more likely than not that some portion or all of
the
deferred income tax assets will not be realized. Management considers factors
such as reversal of deferred income tax liabilities, projected future taxable
income, tax planning strategies, changes in tax law and other
factors. A change to these factors could impact the estimated
valuation allowance and income tax expense.
Under
SFAS No. 109, “Accounting for Income Taxes,” deferred tax assets and
liabilities are determined based on differences between the financial reporting
and tax basis of assets and liabilities, and are measured using enacted tax
rates and laws that will be in effect when the differences are expected to
reverse. SFAS No. 109 provides for the recognition of deferred tax
assets if realization of such assets is more likely than not. Based on the
weight of available evidence, we have provided a valuation allowance against
certain deferred tax assets. The valuation allowance was based on the historical
earnings patterns within individual tax jurisdictions that make it uncertain
that we will have sufficient income in the appropriate jurisdictions to realize
the full value of the assets. We will continue to evaluate the realizability
of
the deferred tax assets on a quarterly basis.
In
June
2006, the Financial Accounting Standards Board issued FASB Interpretation No.
48, “Accounting for Uncertainty in Income Taxes – an interpretation of FASB
Statement No. 109” (hereinafter “FIN 48”), which prescribes a recognition
threshold and measurement attribute for the financial statement recognition
and
measurement of a tax position taken or expected to be taken in a tax
return. FIN 48 also provides guidance on de-recognition,
classification, interest and penalties, accounting in interim periods,
disclosure and transition. FIN 48 is effective for fiscal years
beginning after December 15,
2006. The
adoption of FIN 48 in the first quarter of 2007 did not have any
effect on the consolidated
financial
statements. The
Company files income tax returns in
the U.S. federal jurisdiction and various state jurisdictions. The statute
of
limitations for assessment of federal, state & local income taxes by the
taxing authorities is open for years 2004 to 2006.
33
Item
3. Quantitative and Qualitative Disclosure About Market
Risk
We
have
no material changes to the disclosure on this matter made in our report on
Form
10-K for the fiscal year ended December 31, 2006.
Item
4. Controls and Procedures
The
Company’s principal executive officer and principal financial officer, with the
assistance of other members of the Company’s management, have evaluated the
effectiveness of the design and operation of the Company’s disclosure controls
and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under
the Securities Exchange Act of 1934, as amended) as of the end of the period
covered by this quarterly report. Based upon such evaluation, the
Company’s principal executive officer and principal financial officer have
concluded that the Company’s disclosure controls and procedures are effective as
of the end of the period covered by this quarterly report.
The
Company’s principal executive officer and principal financial officer have also
concluded that there was no change in the Company’s internal control over
financial reporting (as such term is defined in Rule 13a-15(f) under the
Securities Exchange Act of 1934, as amended)
that occurred during the quarter ended June 30, 2007 that has materially
affected, or is reasonably likely to materially affect, the Company’s internal
control over financial reporting.
34
PART
II OTHER INFORMATION
Item
2. Unregistered Sales of Equity Securities and Use of
Proceeds
Issuer
Issuances of Equity Securities
On
April
19, 2007, the Company issued without registration under the Securities Act
of
1933, as amended (the “Securities Act”), to each of Lawrence G. Schafran and
Talton R. Embry, each of whom is a director of the Company, 678 shares of
Company common stock in payment of their quarterly directors
fees. The aggregate value of the 1,356 shares of common stock issued
to Messrs. Schafran and Embry was approximately $3,800 on the date of
issuance. These shares were issued pursuant to exemptions from
registration set forth in Section 4(2) of the Securities Act and Regulation
D
promulgated there under.
This
issuance qualified for exemption from registration under the Securities Act
because (i) each of Messrs. Schafran and Embry is an accredited investor,
(ii)
the Company did not engage in any general solicitation or advertising in
connection with the issuance, and (iii) Messrs. Schafran and Embry received
restricted securities.
Item
6. Exhibits
Exhibit
No.
|
Description
|
|
10.1
|
Agreement
of Lease, dated as of April 5, 2007, between Kampner Realty, LLC,
as
Landlord, and Five Star Products, Inc., as Tenant, for premises located
at
1202 Metropolitan Avenue, Brooklyn, NY (incorporated herein by reference
to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with
the SEC on April 11, 2007)
|
|
10.2
|
Employment
Agreement, dated as of April 5, 2007, between Five Star Group, Inc.
and
Ronald Kampner (incorporated herein by reference to Exhibit 10.2
to the
Registrant’s Current Report on Form 8-K filed with the SEC on April 11,
2007)
|
|
10.3
|
Amendment
to Agreement of Lease between Kampner Realty, LLC, as Landlord, and
Five
Star Products, Inc., as Tenant, for premises located at 1202 Metropolitan
Avenue, Brooklyn, New York, agreed upon and entered into on June
11, 2007
(incorporated herein by reference to Exhibit 10.1 to the Current
Report on
Form 8-K of Five Star Products, Inc. filed with the SEC on June 14,
2007)
|
|
31.1
|
*
|
Certification
of principal executive officer of the Company, pursuant to Securities
Exchange Act Rule 13a-14(a)
|
31.2
|
*
|
Certification
of principal financial officer of the Company, pursuant to Securities
Exchange Act Rule 13a-14(a)
|
32.1
|
*
|
Certifications
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section
906 of
the Sarbanes-Oxley Act of 2002, signed by the principal executive
officer
of the Company and the principal financial officer of the
Company
|
35
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
NATIONAL PATENT DEVELOPMENT
CORPORATION DATE: August 14, 2007 /s/ HARVEY P. EISENName: Harvey P. Eisen Title: Chairman of the Board and
Chief Executive Officer
|
|
|
DATE:
August 14, 2007
|
/s/
IRA J. SOBOTKO
|
|
Name: | Ira J. Sobotko | |
Title: | Vice President, Finance | |
36